`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`STEADYMED LTD,
`
`Petitioner}
`
`V.
`
`UNITED THERAPEUTICS CORPORATION
`
`Patent Owner.
`
`Case IPRZO 16—00006
`
`Patent No. 8,497,3 93 I32
`
`DECLARATION OF JAMES DOWDLE UNDER 37 C.F.R. § 42.6303)
`
`1, James Dowdle declare:
`
`l.
`
`2.
`
`I am fluent in the Japanese and English languages.
`
`I am a Japanese translator from Japanese to English, and have been
`
`working as a translator since 2012.
`
`\N’liS'l"26‘)322-’l‘)4.l
`
`|PR2016-00006
`
`SteadyMed - Exhibit 1019 - Page 1
`
`Liquidia's Exhibit No. 1050
`
`IPR2020-00770 - Page 001
`
`Liquidia's Exhibit No. 1050
`IPR2020-00770 - Page 001
`
`
`
`3.
`
`I received my Bachelor’s Degree in Japanese from Brigham Young
`
`University in 2012. To receive my degree, I was required to do an entire thesis
`
`presentation in Japanese.
`
`I have also lived in Japan, where I worked as an intern
`
`teaching English and studying Japanese literature and culture.
`
`4.
`
`I personally translated a Japanese Patent Application, which
`
`translation is now Ex. 1007, and my translation is a true and accurate translation of
`
`the japanese Patent Application No. 56—122328A (Kawakami), Crystalline Amine
`
`Salt of Methanoprostacyclin Derivative, Manufacturing Method Thereof, and
`
`Purifying Method Thereof.
`
`5.
`
`1 am confident that this translation is true and accurate, because it was
`
`checked by Mr. Boris Levine, who is an experienced Japanese-to—English
`
`translator.
`
`I hereby declare that all statements made herein are of my own personal
`
`knowledge; all statements made on information and belief are believed to be true;
`
`and all statements were made with the knowledge that willful false statements and
`
`the like so made are punishable by fine or imprisonment, or both, under Section
`
`1001 of Title
`
`United States Code.
`
`
`
`
`Ja _, es Dowdl
`
`Technical Language Services, lnc.
`April
`2;;
`, 2016
`
`W125 l“-2(>‘)322~19»l
`
`l
`
`[J
`
`|PR2016-00006
`
`SteadyMed - Exhibit 1019 - Page 2
`
`Liquidia's Exhibit No. 1050
`
`IPR2020-00770 - Page 002
`
`Liquidia's Exhibit No. 1050
`IPR2020-00770 - Page 002
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that a copy of the attached DECLARATION OF
`
`JAMES DOWDLE UNDER 37 C.F.R. § 42.63(B), was served Via electronic mail
`
`to the following:
`
`Stephen B. Maebius
`George Quillin
`FOLEY & LARDNER LLP
`
`UT3 93-IPR@foley.com
`
`Shaun R. Snader
`
`UNITED THERAPEUTICS CORP.
`
`ssnader@unither.com
`
`Douglas Carsten
`Richard Torczon
`
`Robert Delafield
`
`WILSON, SONSINI, GOODRICH & ROSATI
`dcarsten ws
`.com
`
`rtorczon@wsgr.com
`bdelafield ws
`.com
`
`Date: April 29, 2016
`
`Respectfiilly submitted,
`
`/s Stuart E. Pollack /
`
`/s Lisa A. Haile /
`
`Stuart E. Pollack, J .D., Ph.D.
`
`Lisa A. Haile, J.D., Ph.D.
`
`Reg. No. 43,862
`DLA Piper LLP (US)
`
`Reg. No. 38,347
`DLA Piper LLP (US)
`
`WEST\269322494.1
`
`|PR2016-00006
`
`SteadyMed - Exhibit 1019 - Page 3
`
`Liquidia's Exhibit No. 1050
`
`IPR2020-00770 - Page 003
`
`Liquidia's Exhibit No. 1050
`IPR2020-00770 - Page 003
`
`